Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on October 26, 2016. The company is a Nevada corporation focused on proprietary cannabinoid-based therapeutics. The report details a material definitive agreement entered into on the same date.
Key Financial Metrics
The filing discloses a specific financing event rather than periodic financial statements. Key metrics related to this transaction include:
- Aggregate Proceeds: $500,000
- Instrument: 500 shares of Series C Convertible Preferred Stock
- Purchase Price: $1,000 per share
- Conversion Price: $0.40 per share of common stock
- Use of Proceeds: Advancement of proprietary cannabinoid-based therapeutics and general corporate purposes
The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions outside of this specific financing.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement to raise $500,000. This transaction introduces new equity instruments with specific rights, including:
- Anti-dilution Protection: Included in the Series C terms.
- Most Favored Nation Provision: Allows investors to exchange Preferred Shares for securities issued in subsequent financings on the same terms.
- Conversion Limitation: Holders are restricted from acquiring beneficial ownership of more than 4.99% of outstanding common stock (increasable to 9.99% in certain circumstances).
- Lock-up Agreements: Officers and directors are required to enter into lock-up agreements effective upon closing.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use the proceeds to fund the advancement of its proprietary cannabinoid-based therapeutics.
Registration Rights and Contingencies: The company agreed to file a registration statement for the resale of underlying common stock within 30 calendar days of closing. If the registration statement does not become effective within specified time periods, the company is obligated to pay the purchasers a penalty of 2.0% of the aggregate purchase price per month until effectiveness or until Rule 144 restrictions are lifted.
Risks: The financing is subject to customary closing conditions. The "most favored nation" provision may impact the terms of future capital raises.
Investor Verification Checklist
- Verify the closing of the $500,000 financing and the issuance of Series C Convertible Preferred Stock.
- Confirm the filing of the registration statement for resale of underlying shares within the 30-day window to avoid the 2.0% monthly penalty.
- Review the specific terms of the lock-up agreements signed by officers and directors.
- Monitor future capital raises to assess the impact of the "most favored nation" provision on new investor terms.
- Clarify the company's current cash position and runway, as this filing does not provide a balance sheet or cash flow statement.